Lv11
60 积分 2024-05-10 加入
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
2小时前
已完结
泌尿系统肿瘤PD-L1的检测与判读
1个月前
已完结
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring
2个月前
已完结
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics
2个月前
已完结
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer
2个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
3个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
3个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
4个月前
已完结
Inflammasome components as new therapeutic targets in inflammatory disease
5个月前
已完结
皖公网安备34019202002308
